ReP USP - Resultado da busca

Artigo de periodico
Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*) (2019)
Robak, Tadeusz; Huang, Huiqiang; Jin, Jie; Zhu, Jun; Liu, Ting; Samoilova, Olga; Pylypenko, Halyna; Verhoef, Gregor; Siritanaratkul, Noppadol; Osmanov, Evgenii; Pereira, Juliana
Fonte: Leukemia & lymphoma. Unidade: FM
Assuntos: LINFOMA, SOBREVIDA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROBAK, Tadeusz et al. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*). Leukemia & lymphoma, v. 60, n. 1, p. 172-179, 2019Tradução . . Disponível em: https://doi.org/10.1080/10428194.2017.1321750. Acesso em: 21 out. 2024.
APA
Robak, T., Huang, H., Jin, J., Zhu, J., Liu, T., Samoilova, O., et al. (2019). Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*). Leukemia & lymphoma, 60( 1), 172-179. doi:10.1080/10428194.2017.1321750
NLM
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Pereira J. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*) [Internet]. Leukemia & lymphoma. 2019 ; 60( 1): 172-179.[citado 2024 out. 21 ] Available from: https://doi.org/10.1080/10428194.2017.1321750
Vancouver
Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Pereira J. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study(*) [Internet]. Leukemia & lymphoma. 2019 ; 60( 1): 172-179.[citado 2024 out. 21 ] Available from: https://doi.org/10.1080/10428194.2017.1321750
Artigo de periodico
Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study (2018)
Robak, Tadeusz; Jin, Jie; Pylypenko, Halyna; Verhoef, Gregor; Siritanaratkul, Noppadol; Drach, Johannes; Raderer, Markus; Mayer, Jiri; Pereira, Juliana; Tumyan, Gayane
Fonte: Lancet oncology. Unidade: FM
Assuntos: LINFOMA, IMUNOTERAPIA, ESTUDOS RANDOMIZADOS, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROBAK, Tadeusz et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, v. 19, n. 11, p. 1449-1458, 2018Tradução . . Disponível em: https://doi.org/10.1016/S1470-2045(18)30685-5. Acesso em: 21 out. 2024.
APA
Robak, T., Jin, J., Pylypenko, H., Verhoef, G., Siritanaratkul, N., Drach, J., et al. (2018). Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet oncology, 19( 11), 1449-1458. doi:10.1016/S1470-2045(18)30685-5
NLM
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2024 out. 21 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5
Vancouver
Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study [Internet]. Lancet oncology. 2018 ; 19( 11): 1449-1458.[citado 2024 out. 21 ] Available from: https://doi.org/10.1016/S1470-2045(18)30685-5
Artigo de periodico
Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study (2017)
Verhoef, Gregor; Robak, Tadeusz; Huang, Huiqiang; Pylypenko, Halyna; Siritanaratkul, Noppadol; Pereira, Juliana; Drach, Johannes; Mayer, Jiri; Okamoto, Rumiko; Pei, Lixia; Rooney, Brendan; Cakana, Andrew; Velde, Helgi van de; Cavalli, Franco
Fonte: Haematologica. Unidade: FM
Assuntos: LINFOMA, PROGNÓSTICO, SOBREVIVÊNCIA LIVRE DE DOENÇA, ANTINEOPLÁSICOS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
VERHOEF, Gregor et al. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study. Haematologica, v. 102, n. 5, p. 895-902, 2017Tradução . . Disponível em: https://doi.org/10.3324/haematol.2016.152496. Acesso em: 21 out. 2024.
APA
Verhoef, G., Robak, T., Huang, H., Pylypenko, H., Siritanaratkul, N., Pereira, J., et al. (2017). Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study. Haematologica, 102( 5), 895-902. doi:10.3324/haematol.2016.152496
NLM
Verhoef G, Robak T, Huang H, Pylypenko H, Siritanaratkul N, Pereira J, Drach J, Mayer J, Okamoto R, Pei L, Rooney B, Cakana A, Velde H van de, Cavalli F. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study [Internet]. Haematologica. 2017 ; 102( 5): 895-902.[citado 2024 out. 21 ] Available from: https://doi.org/10.3324/haematol.2016.152496
Vancouver
Verhoef G, Robak T, Huang H, Pylypenko H, Siritanaratkul N, Pereira J, Drach J, Mayer J, Okamoto R, Pei L, Rooney B, Cakana A, Velde H van de, Cavalli F. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study [Internet]. Haematologica. 2017 ; 102( 5): 895-902.[citado 2024 out. 21 ] Available from: https://doi.org/10.3324/haematol.2016.152496
Trabalho de evento-resumo periodico
Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study (2014)
Robak, Tadeusz; Huang, Huiqiang; Jim, Jie; Shu, Jun; Liu, Ting; Samailova, Olga S.; Pereira, Juliana; Pylypenko, Halyna; Verhoef, Gregor; Siritanaratkul, Noppadol; Osmanov, Evgenii A.; Alexeeva, Julia; Mayer, Jiri; Hong, Xiaonan; Maeda, Yoshiharu; Rooney, Brendan; van de Velde, Helgi; Cavalli, Franco
Fonte: Blood. Nome do evento: Annual Meeting and Exposition / ASH. Unidade: FM
Assuntos: LINFOMA (TERAPIA), FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO, SOBREVIDA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
ROBAK, Tadeusz et al. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx. Acesso em: 21 out. 2024. , 2014
APA
Robak, T., Huang, H., Jim, J., Shu, J., Liu, T., Samailova, O. S., et al. (2014). Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study. Blood. New York: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx
NLM
Robak T, Huang H, Jim J, Shu J, Liu T, Samailova OS, Pereira J, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov EA, Alexeeva J, Mayer J, Hong X, Maeda Y, Rooney B, van de Velde H, Cavalli F. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study [Internet]. Blood. 2014 ; 124( 21):[citado 2024 out. 21 ] Available from: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx
Vancouver
Robak T, Huang H, Jim J, Shu J, Liu T, Samailova OS, Pereira J, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov EA, Alexeeva J, Mayer J, Hong X, Maeda Y, Rooney B, van de Velde H, Cavalli F. Bortezomib (Btz) dose intensity is the strongest predictor for overall survival (OS) in mantle cell lymphoma (MCL) patients (Pts) not considered for transplantation, receiving frontline Btz plus rituximab, cyclosphosphamide, doxorubicin, and prednisone (VR-CAP) therapy in the phase 3 LYM 3002 study [Internet]. Blood. 2014 ; 124( 21):[citado 2024 out. 21 ] Available from: http://www.hematology.org/Annual-Meeting/Program/Education-Program.aspx

Unidades USP

ReP

Filtros

Autores

Assuntos

Indexado em